Abstract
The anti-PD1 immune checkpoint inhibitor pembrolizumab is an established treatment option for patients with metastatic non-small cell lung cancer (NSCLC) with PD-L1 expression ≥50%. Whilst pembrolizumab therapy may lead to durable responses in some patients, a proportion of patients derive little clinical benefit from treatment. Biomarkers that predict treatment response would assist in clinical decision making in the management of metastatic NSCLC patients. The relationship between cancer and obesity is complex.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
